

September 29

8:00 Welcoming Address Dr Carolyn Owen

SESSION 1: NOVEL THERAPEUTICS

8:10—9:10 Keynote Address

“More Than Just Anti-Leukemic Effects: Impact Of BTK Inhibitors On Normal Cells”

Dr Adrian Wiestner, NIH

9:10-9:40 Next Generation BTK-Inhibitors

Dr. Jennifer Woyach, Ohio State University OH

9:40-10:10 The Future Of PI3kinase Inhibition In CLL

Dr. Jennifer Brown, Dana Farber Cancer Institute, Boston MA

COFFEE

10:25-10:55 Mechanisms Of PI3kinase Immune Toxicities And Strategies For Managing Them

Dr. Steven Coutré, Stanford University, Palo Alto CA

10:55-11:10 Buparlisib In The Treatment Of Relapsed/Refractory CLL (NCIC-IND216 Study)

Dr. Lilian Amrein, Lady Davis Institute-Jewish General Hospital, Montreal QC

11:10-11:30 Mechanisms Of Cardiac Toxicity With Ibrutinib And Strategies For Management

Dr. Graeme Fraser, Juravinski Cancer Centre, Hamilton ON

11:30-11:50 CLL & Telomeres – Survival Of The Fittest

Dr. Lin Yang, University Of Manitoba

LUNCH

SESSION 2: TRANSLATIONAL STUDIES IN CLL

Chair: Versha Banerji

1:00-1:25 Targeting Apoptotic Blocks In CLL And INHL
Dr. Nathalie Johnson, McGill University, Montreal PQ

1:25-1:50 Hematopoiesis In CLL
Dr. Neil Kay, Mayo Clinic, Rochester, MN

1:50 - 2:10 DNA Repair In CLL Cells Treated With Bendamustine
Dr. Sachin Katyal, University Of Manitoba

2:10 – 2:30 Use Of Anti-Malarials In The Treatment Of CLL
Dr. Spencer Gibson, University Of Manitoba

2:30 – 2:50 Epigenetic Landscape Of Progressive CLL
Dr. Deepa Sampath – Ohio State University, OH

COFFEE

SESSION3: TREATMENT OF CLL COMPLICATIONS/DRUG TOXICITIES

Chair: Cindy Toze

3:00-3:25 PD-1 Blockade In Relapsed CLL/Richter's Transformation
Dr. Wei Ding, Mayo Clinic, Rochester

3:25-3:35 Impact Of PD-1 Inhibition In Malignant Melanoma On Primary CLL Patients
Dr. Versha Banerji, University Of Manitoba

3:35 – 3:55 Hodgkin Variant Richter's Transformation In CLL
Dr. Sameer Parikh, Mayo Clinic, Rochester

3:55-4:20 Case Presentations/Discussion Re: Choice Of Novel Agents And Management Of
Common Problems

Dr. Tim Call, Mayo Clinic, Rochester

4:20 – 4:35 Natural History Of CLL In The CLL Clinic

Dr. Sara Beiggi, Cancer Care Manitoba

4:35 – 4:50 The Ibrutinib Experience In A Single Canadian Center

Dr. Versha Banerji, University Of Manitoba

4:50-5:10 Allotransplant in CLL

Dr. Matt Seftel, CancerCare Manitoba

5:10 – 5:20 CLL Patient Advisory Group Update

Jim Burke

5:30-7:00 POSTER PRESENTATION BY TRAINEES AND ALLIED HEALTHCARE PROFESSIONALS

Judges: Gerald Marti, Cindy Toze, Wei Ding

7:15 BANQUET DINNER AND AWARDS CEREMONY

Mr George D Smith Prize For Excellence In CLL Research By A Trainee

FRIDAY, SEPTEMBER 30

7:30 BREAKFAST

SESSION 4: CLL IMMUNOLOGY

Chair Dr. Spencer Gibson

8:00-8:30 Advances In Understanding Of CLL Immunology
Dr. Shawn Kubli, University Health Network, Toronto ON

8:30-9:00 Anti-IL-12 Vaccine Therapy In CLL
Dr. Chris Paige, University Health Network, Toronto.

9:00-9:30 Kinase Inhibitors And Venetoclax
Dr. Sina Opperman, Germany

9:30-9:50 Cholesterol Impact On CLL
Dr Lee Mozessohn, Sunnybrook

9:50 – 10: 10 Immunoglobulins Changes In CLL
Dr. James Johnston, University Of Manitoba

10:10-10:30 Efficacy And Cost Savings With Subcutaneous Immunoglobulin In CLL Patients
Erin Streu, CancerCare Manitoba

COFFEE

SESSION 5: GENETICS/GENOMICS

Chair: Dr. David Spaner

10:50 – 11:15 Ibrutinib Resistance
Dr Amy Johnson

11:15-11:45 DNA Methylation In CLL

Dr. Chris Oakes, Ohio State University

11:45-12:05 A Potential Mechanism For Generating Recurrent Chromosomal Translocations

Dr. Linda Pilarski, University Of Alberta, Edmonton

12:05-12:25 Provincial cohort analysis of del 13q and del11q CLL patients in BC

Dr. Alina Gerrie, BC Cancer Agency/Vancouver General Hospital, Vancouver BC

12:25-12:45 Application Of Next Generation Sequencing For Integrated Diagnostics In CLL

Dr. Graeme Quest, University Health Network, Toronto ON

LUNCH

Final Message – Dr. Carolyn Owen

The Organizing Committee Would Like To Thank Their Sponsors For Their Generous Support Of This Event

abbvie



CSL Behring
Biotherapies for Life™



www.clmeeting.ca